EPS growth is an important number as it indicates the future prospects of Assertio Therapeutics. It is typically displayed as a percentage and called the EPS growth rate, which at this time is hard to estimate, but revenue growth has been -24.20 % over the last twelve months. The higher the EPS growth rate, the higher the value that is added to shareholders and a good reflection on the performance of the management at Assertio Therapeutics.

Assertio Therapeutics is part of the healthcare sector and is part of the drug manufacturers industry. The company CEO is Arthur J. Higgins. Depomed Inc is a specialty pharmaceutical company focused on pain and other conditions and diseases of the central nervous system.

Previous Intraday Performance:

The ASRT shares had a previous change of -4.32% which opened at 5.00 and closed at 4.99. It moved to an intraday high of 5.05 and a low of 4.65.

SeekingAlpha:  Assertio Therapeutics Inc 2018 Q3 – Results – Earnings Call Slides

Historical Performance:

Over the last five trading days, ASRT shares returned -4.32% and in the past 30 trading days it returned -13.45%. Over three months, it changed -31.99%. In one year it has changed -20.11% and within that year its 52-week high was 9.48 and its 52-week low was 4.65. ASRT stock is 7.20% above its 52 Week Low.

Our calculations result in a 200 day moving average of 6.67 and a 50 day moving average of 5.51. Right now, ASRT stock is trading -25.22% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  Assertio Therapeutics Inc 2018 Q3 – Results – Earnings Call Slides


The company has a market cap of $318.7m with 63.9m shares outstanding and a float of 61.3m shares. Trading volume was 1,615,624 shares and has experienced an average volume of 791,688 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for Assertio Therapeutics was -1.63 which ended on 31st of December 2017. Based on 1 analyst estimate, the estimated EPS for the next quarter is -0.11. The trailing twelve month EPS is 0.42, which comes to a trailing twelve month PE of 11.87.

Below was the last reported quarterly earnings per share:
09-30-2018:  0.65
06-30-2018:  -0.33
03-31-2018:  0.48
12-31-2017:  -0.38

Base on our calculations, the intrinsic value per share is 8.28, which means it might be undervalued and has a margin of safety of 39.79%

Indicators Also to Watch:

Based on the latest filings, there is 103.50% of institutional ownership. Short-interest was 0, which was 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio was 0.00.

I calculated the beta to be 1.32

SeekingAlpha:  Apellis Pharma down 17% on hiccup in late-stage study of APL-2

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is 19.93%, return on assets is 4.31%, profit margin is 8.25%, price-to-sales is 0.93 and price-to-book is 1.31.

Company Score Card:

Results are out of six:
 1  : Growth Expectations Result
 0  : Financial Safety Result
 1  : Past Performance Result
 4  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here